This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson Should Break Up Now: Opinion

NEW YORK ( TheStreet) -- As much as I have liked health care giant Johnson & Johnson (JNJ - Get Report), I think the company has reached the point where it no longer deserves the benefit of the doubt that it continues to receive.

Rivals such as Pfizer (PFE), Novartis (NVS) and Covidien (COV) now appear more nimble and adaptable, but Johnson & Johnson comes across as incredibly stubborn for being unwilling to concede that it should break itself up.

Its insistence upon remaining one entity is remarkable when rivals such as Abbott Labs (ABT) and Pfizer have enjoyed positive results from opting to separate their businesses.

What's more, Johnson & Johnson has made some recent mistakes, including product recalls, and until recently its stock performance has been broadly uninspiring.

And in terms of valuation, there are considerably better options available within the sector. In my mind, Johnson & Johnson's current price-to-earnings ratio of 18.8 isn't justified by the company's current growth. Meanwhile, Pfizer and Novartis have lower P/Es.

These two rivals offer gross and operating margins that are either similar to or better than Johnson & Johnson's.

The stumbles that JNJ has suffered over the past five years lend support to those that call for its breaking up into smaller parts. But in disappointing fashion, the company's management continues with its attitude of "we know best."

Will this insistence cause the company to lose some loyal investors for good?

As much as I appreciate a good turnaround story, JNJ does not yet fit the criteria absent its removal of the "too big to succeed" overhang. For as dominant as it has been over the past several decades, it needs to embrace that 2.2% revenue growth is all that analysts are projecting. When has that ever been enough? It's hard to imagine any other company today that has shown more evidence of resting on its laurels.

At the time of publication, the author had no positions in stocks mentioned.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
Richard Saintvilus is a private investor with an information technology and engineering background and has been investing and trading for over 15 years. He employs conservative strategies in assessing equities and appraising value while minimizing downside risk. His decisions are based in part on management, growth prospects, return on equity and price-to-earnings as well as macroeconomic factors. He is an investor who seeks opportunities whether on the long or short side and believes in changing positions as information changes.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $112.45 -0.38%
AAPL $92.24 -1.10%
FB $118.56 0.64%
GOOG $706.56 0.73%
TSLA $211.83 0.14%


Chart of I:DJI
DOW 17,638.22 -22.49 -0.13%
S&P 500 2,044.40 -6.23 -0.30%
NASDAQ 4,692.2070 -24.8870 -0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs